FY2024 Earnings Forecast for Sanofi Issued By Zacks Research

Sanofi (NASDAQ:SNY) – Analysts at Zacks Research increased their FY2024 earnings per share (EPS) estimates for shares of Sanofi in a research report issued on Wednesday, November 13th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $4.31 for the year, up from their prior estimate of $4.12. The consensus estimate for Sanofi’s current full-year earnings is $4.29 per share. Zacks Research also issued estimates for Sanofi’s Q4 2024 earnings at $0.84 EPS, Q1 2026 earnings at $1.17 EPS and Q2 2026 earnings at $1.16 EPS.

Other analysts have also recently issued research reports about the stock. Argus boosted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $47.97 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The firm has a market capitalization of $121.74 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The firm has a 50 day moving average of $54.65 and a 200 day moving average of $52.23.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.55 EPS.

Hedge Funds Weigh In On Sanofi

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Boston Partners lifted its stake in shares of Sanofi by 0.3% in the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after purchasing an additional 33,657 shares during the period. Bank of New York Mellon Corp increased its stake in Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after buying an additional 1,370,232 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC lifted its position in shares of Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Sanofi by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in Sanofi by 26.5% during the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after purchasing an additional 673,172 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.